Viridian's Focus on Quality and Efficacy is Rooted in Our Continuous Research & Development
- Proof of Concept bioavailability and pharmacokinetics
- Optimized bioavailability and pharmacokinetics
- Clinical and Commercial formulation approval
VIR.100 – Migraine: Affecting an estimated 12% of the population, migraine is common and for those that experience a migraine, it can be debilitating. According to the Global Burden of Disease Study (GBD2015), migraines have been ranked the third-highest cause of disability worldwide in males and females under the age of 50. We have initiated a pre-clinical study to understand whether natural pain relief ingredients delivered with our proprietary technology can be a safe and effective treatment.
VIR.200 – Osteoarthritis. In Protocol Development.